• Font Size:
  • Print
Friedman Billings downgraded MedImmune, Inc. (MEDI) Friday morning from Outperform to Market Perform. Of all the analysts covering the stock, Friedman Billings has had the best performance over the past year according to Bloomberg's BARR rankings.

click to enlarge
medi

TickerSense

About this author:
Become a Contributor Submit an Article

ETFs In Focus

  • Long Ideas

  • Short Ideas

  • Cramer's Picks